Preclinical-stage biopharmaceutical company developing precision, ligand-targeted siRNA therapies for cancer
Preclinical-stage biopharmaceutical company developing precision, ligand-targeted siRNA therapies for cancer. Its platform targets cancer-driving PRDM genes and proteins, then uses targeting peptides and protected nanoparticles to deliver nucleic acid drugs to cancer cells while minimizing harm to healthy cells.